Rishi Pukhraj, Verma Aditya, Akhtar Zeeshan, Agrawal Rupesh, Agrawal Ashutosh, Kalluri Bharat Rekha Priya, Rishi Ekta
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, Tamil Nadu, India.
Elite School of Optometry, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Oman J Ophthalmol. 2021 Oct 20;14(3):179-183. doi: 10.4103/ojo.ojo_7_21. eCollection 2021 Sep-Dec.
To analyze choroidal parameters in eyes with diabetic macular edema (DME) treated with intravitreal Ozurdex.
Twenty eyes of 14 patients were included in this prospective study. Optical coherence tomography images were obtained before and 8-10 weeks after intravitreal Ozurdex injection; binarized and subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI) were calculated.
Mean SFCT (treatment naïve; 242.22 ± 32.87 reduced to 218.10 ± 22.10, = 0.158 and previously treated; 330.4 ± 56.72 reduced to 328.93 ± 50.55, = 0.833) and mean CVI (treatment naïve; 0.64 ± 0.03 changed to 0.65 ± 0.04, = 0.583 and previously treated; 0.65 ± 0.05 reduced to 0.64 ± 0.03, = 0.208) showed no significant change.
Intravitreal Ozurdex showed no significant effects on SFCT and CVI in eyes with DME over short term. Larger studies with longer follow-up may allow a better understanding.
分析玻璃体内注射奥瑞珠单抗治疗的糖尿病性黄斑水肿（DME）患者的脉络膜参数。
本前瞻性研究纳入了14例患者的20只眼。在玻璃体内注射奥瑞珠单抗之前和之后8 - 10周获取光学相干断层扫描图像；计算二值化和黄斑中心凹下脉络膜厚度（SFCT）以及脉络膜血管指数（CVI）。
平均SFCT（初治患者；从242.22±32.87降至218.10±22.10，P = 0.158；既往治疗患者；从330.4±56.72降至328.93±50.55，P = 0.833）和平均CVI（初治患者；从0.64±0.03变为0.65±0.04，P = 0.583；既往治疗患者；从0.65±0.05降至0.64±0.03，P = 0.208）均无显著变化。
短期内，玻璃体内注射奥瑞珠单抗对DME患者的SFCT和CVI无显著影响。进行更长随访期的更大规模研究可能有助于更好地理解。
